ogical Versus Absolute Lymphocyte Count-guided Preemptive Therapy for CMV Prevention in Solid Organ Transplant Recipients: A Randomized Controlled Trial
Phase 3
Completed
- Conditions
- All adult Thai SOT recipientsCMV preemptive immunity immunocompromised
- Registration Number
- TCTR20220720007
- Lead Sponsor
- Faculty of Medicine Ramathibodi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
All adult Thai CMV-seropositive SOT recipients
Exclusion Criteria
Unwilling to participate, CMV D+/R-, receiving ATG therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Free from CMV infection 6 months CMV Viral load
- Secondary Outcome Measures
Name Time Method Cost effectiveness 6 months Baht